Riociguat for the treatment of pulmonary hypertension

Expert Opinion on Investigational Drugs

Volumn 20, Issue 4, 2011, Pages 567-576

  Schermuly, Ralph T ^a,b   Janssen, Wiebke ^a   Weissmann, Norbert ^b   Stasch, Johannes Peter ^c,d   Grimminger, Friedrich ^b   Ghofrani, Hossein Ardeschir ^b  

^a MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

^b JUSTUS LIEBIG UNIVERSITY   (Germany)

^c Pharma Research Centre   (Germany)

^d MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

chronic thromboembolic pulmonary hypertension; cyclic guanosine monophosphate; pulmonary arterial hypertension; pulmonary hypertension; riociguat; soluble guanylate cyclase

Indexed keywords

4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; CALCIUM CHANNEL BLOCKING AGENT; CYCLIC GMP; GUANOSINE TRIPHOSPHATE; GUANYLATE CYCLASE; IMATINIB; NITRIC OXIDE; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; RIOCIGUAT;

BLOOD PRESSURE REGULATION; CELL PROLIFERATION; CLINICAL EFFECTIVENESS; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOTHELIUM INJURY; FLUSHING; GAS EXCHANGE; HOT FLUSH; HUMAN; HYPOTENSION; IN VITRO STUDY; LONG TERM CARE; LUNG RESISTANCE; LUNG VASOCONSTRICTION; NONHUMAN; NOSE CONGESTION; ORTHOSTATIC HYPOTENSION; PATHOGENESIS; PULMONARY ARTERY; PULMONARY HYPERTENSION; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; SYSTOLIC BLOOD PRESSURE; VASODILATATION;

ANIMALS; ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; GUANYLATE CYCLASE; HUMANS; HYPERTENSION, PULMONARY; MODELS, CARDIOVASCULAR; PYRAZOLES; PYRIMIDINES; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 79952654621     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.2011.565048     Document Type: Review

References (60)

1. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2009;54(Suppl 1):S43-54
2. Cogan JD, Pauciulo MW, Batchman AP, et al. High frequency of BMPR2 exonic deletions/duplications in familial pulmonary arterial hypertension. Am J Respir Crit Care Med 2006;174:590-8 (Pubitemid 44330553)
3. Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43(12 Suppl S):13S-24S
4. Morrell NW, Adnot S, Archer SL, et al. Cellular and molecular basis of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54(Suppl 1):S20-31
5. Rabinovitch M. Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest 2008;118:2372-9 (Pubitemid 351949764)
6. Stenmark KR, Gerasimovskaya E, Nemenoff RA, Das M. Hypoxic activation of adventitial fibroblasts: role in vascular remodeling. Chest 2002;122(Suppl 6):326S-334S
7. Tuder R, Voelkel N. Pulmonary hypertension and inflammation. J Lab Clin Med 2010;132:16-24
8. Sitbon O, Humbert M, Jais X, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005;111:3105-11 (Pubitemid 40847788)
9. Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347:322-9 (Pubitemid 34815354)
10. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903 (Pubitemid 34984638)
11. Ghofrani HA, Wiedemann R, Rose F, et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002;360:895-900 (Pubitemid 35283832)
12. Galie N, Hoeper MM, Humbert M, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009;30:2493-537
13. Humbert M, Segal ES, Kiely DG, et al. Results of European post-marketing surveillance of bosentan in pulmonary hypertension. Eur Respir J 2007;30:338-44 (Pubitemid 47194187)
14. Bhatia S, Frantz RP, Severson CJ, et al. Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy. Mayo Clin Proc 2003;78:1207-13 (Pubitemid 37193511)
15. Chockalingam A, Gnanavelu G, Venkatesan S, et al. Efficacy and optimal dose of sildenafil in primary pulmonary hypertension. Int J Cardiol 2005;99:91-5 (Pubitemid 40261030)
16. Galie N, Manes A, Negro L, et al. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 2009;30:394-403
17. Hoeper MM, Barbera JA, Channick RN, et al. Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension. J Am Coll Cardiol 2009;54(Suppl 1):S85-96
18. Rosenkranz S. Pulmonary hypertension: current diagnosis and treatment. Clin Res Cardiol 2007;96:527-41 (Pubitemid 47106497)
19. Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 2005;353:1412-13 (Pubitemid 41362714)
20. Schermuly RT, Dony E, Ghofrani HA, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005;115:2811-21 (Pubitemid 41434408)
21. Ghofrani HA, Schermuly RT, Weissmann N, et al. Reverse remodeling - paradigm shift in the treatment of pulmonary hypertension. Dtsch Med Wochenschr 2006;131:871-4
22. Ghofrani HA, Osterloh IH, Grimminger F. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat Rev Drug Discov 2006;5:689-702 (Pubitemid 44151606)
23. Ghofrani HA, Pepke-Zaba J, Barbera JA, et al. Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. J Am Coll Cardiol 2004;43(12 Suppl S):68S-72S
24. Grimminger F, Spriestersbach R, Weissmann N, et al. Nitric oxide generation and hypoxic vasoconstriction in buffer-perfused rabbit lungs. J Appl Physiol 1995;78:1509-15
25. Derbyshire ER, Marletta MA. Biochemistry of soluble guanylate cyclase. Handb Exp Pharmacol 2009;191:17-31
26. Dumitrascu R, Weissmann N, Ghofrani HA, et al. Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling. Circulation 2006;113:286-95
27. Denninger JW, Marletta MA. Guanylate cyclase and the NO/cGMP signaling pathway. Biochim Biophys Acta 1999;1411:334-50 (Pubitemid 29221959)
28. Waldman SA, Murad F. Cyclic GMP synthesis and function. Pharmacol Rev 1987;39:163-96 (Pubitemid 18045484)
29. Zabel U, Hausler C, Weeger M, Schmidt HH. Homodimerization of soluble guanylyl cyclase subunits. Dimerization analysis using a glutathione s-transferase affinity tag. J Biol Chem 1999;274:18149-52
30. Wedel B, Humbert P, Harteneck C, et al. Mutation of His-105 in the beta 1 subunit yields a nitric oxide-insensitive form of soluble guanylyl cyclase. Proc Natl Acad Sci USA 1994;91:2592-6
31. Friebe A, Koesling D. Regulation of nitric oxide-sensitive guanylyl cyclase. Circ Res 2003;93:96-105 (Pubitemid 36919696)
32. Hoffmann LS, Schmidt PM, Keim Y, et al. Distinct molecular requirements for activation or stabilization of soluble guanylyl cyclase upon haem oxidation-induced degradation. Br J Pharmacol 2009;157:781-95
33. Melichar VO, Behr-Roussel D, Zabel U, et al. Reduced cGMP signaling associated with neointimal proliferation and vascular dysfunction in late-stage atherosclerosis. Proc Natl Acad Sci USA 2004;101:16671-6 (Pubitemid 39557771)
34. Stasch JP, Schmidt PM, Nedvetsky PI, et al. Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J Clin Invest 2006;116:2552-61 (Pubitemid 44330154)
35. Evgenov OV, Pacher P, Schmidt PM, et al. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov 2006;5:755-68 A comprehensive review of the NO-sGC-CGMP pathway, the molecular mechanisms of sGC stimulation, and the therapeutic potential of sGC stimulators.
36. Stasch JP, Hobbs AJ. NO-independent, haem-dependent soluble guanylate cyclase stimulators. Handb Exp Pharmacol 2009;(191):277-308
37. Evgenov OV, Kohane DS, Bloch KD, et al. Inhaled agonists of soluble guanylate cyclase induce selective pulmonary vasodilation. Am J Respir Crit Care Med 2007;176:1138-45 (Pubitemid 350223760)
38. Krasuski RA, Warner JJ, Wang A, et al. Inhaled nitric oxide selectively dilates pulmonary vasculature in adult patients with pulmonary hypertension, irrespective of etiology. J Am Coll Cardiol 2000;36:2204-11
39. Schermuly RT, Kreisselmeier KP, Ghofrani HA, et al. Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am J Respir Crit Care Med 2004;169:39-45 (Pubitemid 38233887)
40. Black SM, Sanchez LS, Mata-Greenwood E, et al. sGC and PDE5 are elevated in lambs with increased pulmonary blood flow and pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol 2001;281:L1051-7
41. Giordano D, De Stefano ME, Citro G, et al. Expression of cGMP-binding cGMP-specific phosphodiesterase (PDE5) in mouse tissues and cell lines using an antibody against the enzyme amino-terminal domain. Biochim Biophys Acta 2001;1539:16-27 (Pubitemid 32522866)
42. Hanson KA, Burns F, Rybalkin SD, et al. Developmental changes in lung cGMP phosphodiesterase-5 activity, protein, and message. Am J Respir Crit Care Med 1998;158:279-88 (Pubitemid 28337192)
43. Maclean MR, Johnston ED, McCulloch KM, et al. Phosphodiesterase isoforms in the pulmonary arterial circulation of the rat: changes in pulmonary hypertension. J Pharmacol Exp Ther 1997;283:619-24 (Pubitemid 27514618)
44. Wharton J, Strange JW, Moller GM, et al. Antiproliferative effects of phosphodiesterase type 5 inhibition in human pulmonary artery cells. Am J Respir Crit Care Med 2005;172:105-13 (Pubitemid 40923321)
45. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005;353:2148-57 (Pubitemid 41653106)
46. Ko FN, Wu CC, Kuo SC, et al. YC-1, a novel activator of platelet guanylate cyclase. Blood 1994;84:4226-33
47. Friebe A, Koesling D. Mechanism of YC-1-induced activation of soluble guanylyl cyclase. Mol Pharmacol 1998;53:123-7 (Pubitemid 28068379)
48. Friebe A, Schultz G, Koesling D. Sensitizing soluble guanylyl cyclase to become a highly CO-sensitive enzyme. EMBO J 1996;15:6863-8 (Pubitemid 27023257)
49. Stasch JP, Becker EM, Alonso-Alija C, et al. NO-independent regulatory site on soluble guanylate cyclase. Nature 2001;410:212-15 The first description of the NO-independent regulatory site of sGC and the stimulation of sGC via this site by BAY 41-2272.
50. Evgenov OV, Ichinose F, Evgenov NV, et al. Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs. Circulation 2004;110:2253-9 An early demonstration of the pulmonary hemodynamic benefits of sGC stimulation (with BAY 41-2272) in an animal model of PH in vivo.
51. Deruelle P, Balasubramaniam V, Kunig AM, et al. BAY 41-2272, a direct activator of soluble guanylate cyclase, reduces right ventricular hypertrophy and prevents pulmonary vascular remodeling during chronic hypoxia in neonatal rats. Biol Neonate 2006;90:135-44 (Pubitemid 44197481)
52. Mittendorf J, Weigand S, Alonso-Alija C, et al. Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension. ChemMedChem 2009;4:853-65
53. Frey R, Muck W, Unger S, et al. Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63-2521: an ascending-dose study in healthy male volunteers. J Clin Pharmacol 2008;48:926-34 (Pubitemid 352009497)
54. Schermuly RT, Stasch JP, Pullamsetti SS, et al. Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. Eur Respir J 2008;32:881-91 A paper demonstrating that in animal models of PH, riociguat improved pulmonary hemodynamics and prevented and even partially reversed features of adverse structural remodeling.
55. Frey R, Muck W, Unger S, et al. BAY 63-2521, an oral soluble guanylate cyclase stimulator, has a favourable safety profile and decreases peripheral vascular resistance in healthy male volunteers. BMC Pharmacol 2007;7(Suppl 1):abstract P20
56. Grimminger F, Weimann G, Frey R, et al. First acute haemodynamic study of soluble guanylate cyclase stimulator riociguat in pulmonary hypertension. Eur Respir J 2009;33:785-92
57. Frey R, Muck W, Kirschbaum N, et al. Riociguat (BAY 63-2521) and warfarin: a pharmacodynamic and pharmacokinetic interaction study. J Clin Pharmacol 2010: published online 27 August 2010, doi: 10.1177/0091270010378119
58. Ghofrani HA, Hoeper MM, Halank M, et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: a phase II study. Eur Respir J 2010;36:792-9 The report of the Phase II trial of riociguat, demonstrating good tolerability and significant improvements in pulmonary hemodynamics and exercise capacity in patients with PAH or CTEPH.
59. Ghofrani A, Hoeper M, Halank M, et al. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: first long-term extension data from a Phase II study. Am J Respir Crit Care Med 2010;181:A6770
60. Hoeper M, Halank M, Wilkens H, et al. Riociguat for patients with pulmonary hypertension associated with interstitial lung disease. Am J Respir Crit Care Med 2010;181:A2562